← Back to Clinical Trials
Recruiting NCT04765150

NCT04765150 Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04765150
Status Recruiting
Phase
Sponsor Jonsson Comprehensive Cancer Center
Condition Prostate Carcinoma
Study Type OBSERVATIONAL
Enrollment 275 participants
Start Date 2021-04-01
Primary Completion 2027-06-01

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
3 Tesla Magnetic Resonance ImagingElectronic Health Record Review

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 275 participants in total. It began in 2021-04-01 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.

Eligibility Criteria

Inclusion Criteria: * Male patients 18 years of age and older * Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer * Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA) * Ability to provide consent Exclusion Criteria: * Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia) * Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent * Prior radiotherapy

Contact & Investigator

Central Contact

Nashla Barroso

✉ nbarroso@mednet.ucla.edu

📞 (310) 794-7952

Principal Investigator

Kyung H Sung, PhD

PRINCIPAL INVESTIGATOR

UCLA / Jonsson Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT04765150 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04765150 currently recruiting?

Yes, NCT04765150 is actively recruiting participants. Contact the research team at nbarroso@mednet.ucla.edu for enrollment information.

Where is the NCT04765150 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT04765150 clinical trial?

NCT04765150 is sponsored by Jonsson Comprehensive Cancer Center. The principal investigator is Kyung H Sung, PhD at UCLA / Jonsson Comprehensive Cancer Center. The trial plans to enroll 275 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology